Abstract: Co-crystals comprising the Nuclear receptor related 1 protein-ligand binding domain (Nurr1-LBD) and a cyclopentenone prostaglandin are provided. Also provided are methods of identifying or designing Nurr1-modulating ligands and compounds based on the crystal structures described herein as well as the applications of said ligands and compounds as Nurr1 modulators or medicaments.

Abstract: Co-crystals comprising the Nuclear receptor related 1 protein-ligand binding domain (Nurr1-LBD) and a cyclopentenone prostaglandin are provided. Also provided are methods of identifying or designing Nurr1-modulating ligands and compounds based on the crystal structures described herein as well as the applications of said ligands and compounds as Nurr1 modulators or medicaments.

Abstract: The present invention relates to an anti-inflammatory composition, and more particularly to an anti-inflammatory composition containing, as an active ingredient, a compound represented by Formula 1 or a salt thereof, wherein the anti-inflammatory composition may inhibit inflammatory response even at an early stage by inhibiting the interaction between CD14 and LPS and blocking the expression of CD14 and the expression of TNF? and IL-1?, which are the key factors in inflammatory response, and may also regulate the expression of important factors, such as CCL2 (MCP-1), CCL7 (MCP-3), CXCL2, CHOP and NOX1, which are involved in inflammatory response.

Abstract: The present invention relates to pharmaceutical composition for the prevention or treatment of a disease, disorder, or condition associated with Nurr1, including, as an active ingredient, a prostaglandin analog or a pharmaceutically acceptable salt thereof, wherein the compound has excellent effects in inducing Nurr1, and thus, can be useful as a pharmaceutical composition for the prevention or treatment of a disease, disorder, or condition associated with Nurr1, in particular, cancer, autoimmune disease such as rheumatoid arthritis, schizophrenia, manic depression and neurodegenerative disease such as Alzheimers disease or Parkinson's disease.

Abstract: The present invention relates to an anti-inflammatory composition, and more particularly to an anti-inflammatory composition containing, as an active ingredient, a compound represented by Formula 1 or a salt thereof, wherein the anti-inflammatory composition may inhibit inflammatory response even at an early stage by inhibiting the interaction between CD14 and LPS and blocking the expression of CD14 and the expression of TNF? and IL-1?, which are the key factors in inflammatory response, and may also regulate the expression of important factors, such as CCL2 (MCP-1), CCL7 (MCP-3), CXCL2, CHOP and NOX1, which are involved in inflammatory response.

Abstract: A pharmaceutical composition contains the chromone derivative of Chemical Formula 1 and a pharmaceutically acceptable salt as an active ingredient, thus effectively inhibiting the activation of EMT to thereby enable the effective suppression of a disease caused by fibrosis of an organ or tissue in vivo due to the activation of EMT.

Abstract: A pharmaceutical composition contains the chromone derivative of Chemical Formula 1 and a pharmaceutically acceptable salt as an active ingredient, thus effectively inhibiting the activation of EMT to thereby enable the effective suppression of a disease caused by fibrosis of an organ or tissue in vivo due to the activation of EMT.

Abstract: Co-crystals comprising the Nuclear receptor related 1 protein-ligand binding domain (Nurr1-LBD) and a cyclopentenone prostaglandin are provided. Also provided are methods of identifying or designing Nurr1-modulating ligands and compounds based on the crystal structures described herein as well as the applications of said ligands and compounds as Nurr1 modulators or medicaments.

Abstract: The present invention relates to a novel compound and a composition for the prevention, alleviation or treatment of fibrosis or non-alcoholic steatohepatitis, which contains the compound as an active ingredient, and more particularly to a novel compound of Formula 1, which has an excellent effect on the prevention, alleviation or treatment of fibrosis, and to a composition for the prevention, alleviation or treatment of fibrosis or non-alcoholic steatohepatitis, which contains the compound as an active ingredient. The novel compound can regulate the activation of EMT (epithelial-mesenchymal transition) by effectively regulating the expression of snail and vimentin which are regulators of EMT, and thus can effectively prevent, alleviate or treat fibrosis. Furthermore, the novel compound has very good pharmacokinetics. In addition, the novel compound of the present invention can effectively inhibit fibrosis of liver cells, and thus can also effectively alleviate or treat non-alcoholic steatohepatitis.

Abstract: A compound represented by the following Formula 1 or a pharmaceutically acceptable salt thereof: wherein R1 is a substituted or unsubstituted C1-5 linear or branched alkyl, a C5-6 cycloalkyl, a C5-6 cycloalkyl containing at least one heteroatom selected from among O and N, a substituted or unsubstituted C6-12 aryl, or a C5-6 heteroaryl containing at least one heteroatom selected from among O and N; R2 is hydrogen, ethyl, acetyl, acetoxy, carboxy, benzoyloxy or 3,4,5-trihydroxybenzoyloxy; and R3 to R5 are each independently hydrogen, hydroxyl, methyl, methoxy, acetoxy, carboxy or benzoyloxy.

Abstract: A pharmaceutical composition contains the chromone derivative of Chemical Formula 1 and a pharmaceutically acceptable salt as an active ingredient, thus effectively inhibiting the activation of EMT to thereby enable the effective suppression of a disease caused by fibrosis of an organ or tissue in vivo due to the activation of EMT.

Abstract: A pharmaceutical composition contains the chromone derivative of Chemical Formula 1 and a pharmaceutically acceptable salt as an active ingredient, thus effectively inhibiting the activation of EMT to thereby enable the effective suppression of a disease caused by fibrosis of an organ or tissue in vivo due to the activation of EMT.

Abstract: Mutant peptides derived from wild-type human Bcl-2 are disclosed. Assays to identify substances which block the ability of Bcl-2 to inhibit apoptosis also are disclosed.